Lb Pharmaceuticals (LBRX) Return on Capital Employed (2025 - 2026)
Lb Pharmaceuticals' quarterly Return on Capital Employed came in at 11.51% in Q1 2026, down 40.14% quarter-over-quarter from 8.21% in Q4 2025.
Lb Pharmaceuticals has reported Return on Capital Employed for 2 years, with the latest figure at 11.51% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed changed N/A year-over-year to 11.51%; the trailing twelve-month figure through Mar 2026 stood at 11.51% (changed N/A YoY), and the FY2025 full-year result was 15.2%, changed N/A from the prior year.
- Return on Capital Employed for Q1 2026 stood at 11.51%, down from 8.21% in the prior quarter.
- The five-year high for Return on Capital Employed was 8.21% in Q4 2025, with the low at 11.51% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Lb Pharmaceuticals | 789.92 Mn | 789.92 Mn | - | -11.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.51% |
| Dec 31, 2025 | -8.21% |